Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy
Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2814-2825
DOI: 10.1016/j.jtha.2026.04.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Clotilde Martin und 5 weiteren Autor:innen. Beteiligte Einrichtung: UR4609 Hemostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France. Hauptthemen laut MEDLINE: Synovitis, Methotrexate, Factor IX, Hemophilia B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Octapharma AG, Octapharma, CSL Behring.
Abstract (Originalsprache)
BACKGROUND: In severe hemophilia, recurrent hemarthroses lead to hemophilic arthropathy (HArt), characterized by chronic synovitis and cartilage destruction, reminiscent of rheumatoid arthritis. Unlike inflammatory synovitis, HArt lacks disease-modifying, joint-directed, targeted therapies. OBJECTIVE: To assess whether methotrexate (MTX), a reference treatment for inflammatory synovitis, can reduce joint damage when combined with extended half-life factor IX (EHL-FIX) prophylaxis in a murine model of hemophilia B. METHODS: Hemophilia B mice underwent 3 biweekly knee joint punctures to induce recurrent hemarthroses. In part 1, mice received either EHL-FIX prophylaxis alone (100 IU/kg intravenously every 3 days) or EHL-FIX combined with MTX (20 mg/kg subcutaneously once weekly) for 6 weeks as prophylaxis in an attempt to prevent HArt. In part 2, MTX was delayed until after 3 joint punctures. Joint outcomes were assessed using histology and magnetic resonance imaging scans. RESULTS: Knee diameter measurements and magnetic resonance imaging scans confirmed successful induction of joint bleeding and synovitis in all injured mice in both parts. Prophylactic MTX combined with EHL-FIX reduced the severity of the synovitis, significantly reduced the vascular density in the synovial pannus, and decreased the degree of cartilage damage compared with EHL-FIX alone. Following targeted treatment of chronic synovitis, combined FIX + MTX therapy resulted in significantly reduced synovial hyperplasia, vascularity, and macrophage infiltration. No differences in cartilage erosion and proteoglycan loss were observed. CONCLUSION: MTX combined with FIX prophylaxis limits cartilage damage and pathologic synovial angiogenesis in experimental HArt, supporting its evaluation as a potential disease-modifying adjunct therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UR4609 Hemostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France.
- Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, Illinois, USA.
- UR4609 Hemostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France; French Reference Centre for Hemophilia, Louis Pradel Hospital, Lyon, France. Electronic address: ydargaud@univ-lyon1.fr.
Förderung
- Octapharma AG
- Octapharma
- CSL Behring
Zitieren
APA
Martin, C., Valentino, L. A., Martinez, L., Souviraa-Labastie, M., Leuci, A., & Dargaud, Y. (2026). Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy. Journal of Thrombosis and Haemostasis, 24(8), 2814-2825. https://doi.org/10.1016/j.jtha.2026.04.033
Vancouver
Martin C, Valentino LA, Martinez L, Souviraa-Labastie M, Leuci A, Dargaud Y. Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy. Journal of Thrombosis and Haemostasis. 2026;24(8):2814-2825. doi:10.1016/j.jtha.2026.04.033
BibTeX
@article{Martin2026,
author = {Martin, Clotilde and Valentino, Leonard A and Martinez, Lilou and Souviraa-Labastie, Matthieu and Leuci, Alexandre and Dargaud, Yesim},
title = {Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {8},
pages = {2814--2825},
doi = {10.1016/j.jtha.2026.04.033}
}
EUVIMED